A Research Study Looking at Kidney and Heart Health in Adults With Type 2 Diabetes and Chronic Kidney Disease Treated With Semaglutide in China

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 300 participants.

Also called NCT07900438

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 300 participants (planned count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07900438
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07900438. Allocation not applicable; no masking; primary purpose treatment. Start 2026-10-12 (actual); primary completion 2029-12-20 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Research Study Looking at Kidney and Heart Health in Adults With Type 2 Diabetes and Chronic Kidney Disease Treated With Semaglutide in China
Condition
Cardiovascular Risk
Intervention (Drug)
Semaglutide
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct07900438
Content hash
bc5edc5d5aafd761039fc88eec63a1b28e8b169e30097b0a69a7f35e4f972793